Update on the use of immunoglobulin in human disease: A review of evidence

Elena E. Perez; Jordan S. Orange; Francisco Bonilla; Javier Chinen; Ivan K. Chinn; Morna Dorsey; Yehia El-Gamal; Terry O. Harville; Elham Hossny; Bruce Mazer; Robert Nelson; Elizabeth Secord; Stanley C. Jordan; E. Richard Stiehm; Ashley A. Vo; Mark Ballow

doi:10.1016/j.jaci.2016.09.023

Update on the use of immunoglobulin in human disease: A review of evidence

Elena E. Perez
, Jordan S. Orange
, Francisco Bonilla
, Javier Chinen
, Ivan K. Chinn
, Morna Dorsey
, Yehia El-Gamal
, Terry O. Harville
, Elham Hossny
, Bruce Mazer
, Robert Nelson
, Elizabeth Secord
, Stanley C. Jordan
, E. Richard Stiehm
, Ashley A. Vo
, Mark Ballow

Pediatrics

Allergy Associates of the Palm Beaches
Texas Children's Hospital Houston
Boston Children's Hospital
University of California at San Francisco
Ain Shams University
University of Arkansas at Little Rock
McGill University
Indiana University Bloomington
Children's Hospital of Michigan
University of California at Los Angeles
Cedars-Sinai Medical Center

Research output: Contribution to journal › Article › peer-review

605 Scopus citations

Abstract

Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.

Original language	English
Pages (from-to)	S1-S46
Journal	Journal of Allergy and Clinical Immunology
Volume	139
Issue number	3
DOIs	https://doi.org/10.1016/j.jaci.2016.09.023
State	Published - Mar 1 2017

Keywords

IGIV
IVIG
Immune globulin
SCIG
adverse events
autoimmunity
immune modulating
immunoglobulin
immunomodulation
primary immunodeficiency
transfusion

Access to Document

10.1016/j.jaci.2016.09.023

Cite this

Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., Nelson, R., Secord, E., Jordan, S. C., Stiehm, E. R., Vo, A. A., & Ballow, M. (2017). Update on the use of immunoglobulin in human disease: A review of evidence. Journal of Allergy and Clinical Immunology, 139(3), S1-S46. https://doi.org/10.1016/j.jaci.2016.09.023

@article{c14e3ed50e3b493082e2b4abc42eb5b9,

title = "Update on the use of immunoglobulin in human disease: A review of evidence",

abstract = "Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.",

keywords = "IGIV, IVIG, Immune globulin, SCIG, adverse events, autoimmunity, immune modulating, immunoglobulin, immunomodulation, primary immunodeficiency, transfusion",

author = "Perez, \{Elena E.\} and Orange, \{Jordan S.\} and Francisco Bonilla and Javier Chinen and Chinn, \{Ivan K.\} and Morna Dorsey and Yehia El-Gamal and Harville, \{Terry O.\} and Elham Hossny and Bruce Mazer and Robert Nelson and Elizabeth Secord and Jordan, \{Stanley C.\} and Stiehm, \{E. Richard\} and Vo, \{Ashley A.\} and Mark Ballow",

note = "Publisher Copyright: {\textcopyright} 2016 American Academy of Allergy, Asthma \& Immunology",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.jaci.2016.09.023",

language = "English",

volume = "139",

pages = "S1--S46",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "3",

}

Perez, EE, Orange, JS, Bonilla, F, Chinen, J, Chinn, IK, Dorsey, M, El-Gamal, Y, Harville, TO, Hossny, E, Mazer, B, Nelson, R, Secord, E, Jordan, SC, Stiehm, ER, Vo, AA & Ballow, M 2017, 'Update on the use of immunoglobulin in human disease: A review of evidence', Journal of Allergy and Clinical Immunology, vol. 139, no. 3, pp. S1-S46. https://doi.org/10.1016/j.jaci.2016.09.023

TY - JOUR

T1 - Update on the use of immunoglobulin in human disease

T2 - A review of evidence

AU - Perez, Elena E.

AU - Orange, Jordan S.

AU - Bonilla, Francisco

AU - Chinen, Javier

AU - Chinn, Ivan K.

AU - Dorsey, Morna

AU - El-Gamal, Yehia

AU - Harville, Terry O.

AU - Hossny, Elham

AU - Mazer, Bruce

AU - Nelson, Robert

AU - Secord, Elizabeth

AU - Jordan, Stanley C.

AU - Stiehm, E. Richard

AU - Vo, Ashley A.

AU - Ballow, Mark

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.

AB - Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.

KW - IGIV

KW - IVIG

KW - Immune globulin

KW - SCIG

KW - adverse events

KW - autoimmunity

KW - immune modulating

KW - immunoglobulin

KW - immunomodulation

KW - primary immunodeficiency

KW - transfusion

UR - https://www.scopus.com/pages/publications/85009375131

U2 - 10.1016/j.jaci.2016.09.023

DO - 10.1016/j.jaci.2016.09.023

M3 - Article

C2 - 28041678

AN - SCOPUS:85009375131

SN - 0091-6749

VL - 139

SP - S1-S46

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 3

ER -

Update on the use of immunoglobulin in human disease: A review of evidence

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this